Dr Chloe James

Senior Lecturer in Medical Microbiology


Born in Liverpool, England, 1976, I studied Medical Microbiology (BSc Hons) at The University of Edinburgh and was awarded a PhD from the School of Biological Sciences at the University of Liverpool, for work on bacteriophages of E. coli O157. I had postdoctoral research positions at the Institute of Infection and Global Health in Liverpool; Facultés de Médecine et de Pharmacie, Universite de La Mediterranne, Marseille, France; and The Department of Oral Biology, University of Florida, USA. Since November 2012, I have been based at the University of Salford working primarily within the research field of bacterial pathogens and bacterial viruses.


I contribute towards the teaching and delivery of undergraduate projects and modules on the BSc (Hons) courses in Human Biology and Infectious Diseases; Biomedical Science; Biochemistry; and Biology. I am also currently co-supervising PhD students, primarily in the research the field of medical microbiology.

Research Interests

My chief research interests lie in bacterial pathogenicity, development and spread of antibiotic resistance and in how microbial evolution is driven by interaction with microbial communities and their environments. Specifically I have worked on molecular aspects of pathogenicity, regulation and antibiotic resistance in Escherichia coli, Porphyromonas gingivalis, Streptococcus gordonii; Enterobacter aerogenes; Pseudomonas aeruginosa; Campylobacter jejuni.

I am particularly interested in Gram-negative bacteria in multi-species biofilms, and in bacteriophages. I determined that shigatoxigenic phages are able to infect a broad range of bacterial hosts. My most recent publications focus on the characterization of several temperate bacteriophages that play a role in the competitiveness of the opportunistic pathogen, Pseudomonas aeruginosa in the Cystic Fibrosis lung environment.

Qualifications and Memberships

Member of The Society for General Microbiology since 1999.



1. Characterisation of three active prophages from an epidemic strain of Pseudomonas aeruginosa (2012) BMC Microbiology (12) 216-28

2. Use of artificial sputum medium to test antibiotic efficacy against Pseudomonas aeruginosa in conditions more relevant to the cystic fibrosis lung (2012) The Journal of Visualised Experiments 64:e385

3. Novel therapeutic strategies to counter Pseudomonas aeruginosa infections (2012)  Expert Reviews of Anti Infective Therapy (10) 219–235

4. The effect of antibiotic treatment on bacteriophage production by a cystic fibrosis epidemic strain of Pseudomonas aeruginosa. (2011) Antimicrob Agents Chemother (55) 426-8

5. How b-Lactam Antibiotics Enter Bacteria: A Dialogue with the Porins (2009) PLoS ONE 4 (5). e5453. doi:10.1371

6. The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria. (2008)  Nat Rev Microbiol. (12) 893-903